Should I buy United Therapeutics (UTHR) stock or is it too late?

United Therapeutics · Health Care · price $528

See the full United Therapeutics (UTHR) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: B of A Securities — 74% of its targets hit on this sector (105 calls tested). It aims for $613 (+16 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).

The 2 reliable analysts $645+22 %

The 7 other firms $660+25 %

How to read it: the 2 reliable firms are not filtered by optimism — 2 aim above the price, 0 below, hence their $645 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on United Therapeutics

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Ladenburg Thalmann	100 %	+29.1 %	8	$344 -35%
JP Morgan	58 %	+27.4 %	12	$687 +30%
UBS	71 %	+26.9 %	7	$705 +34%
Wedbush	70 %	+26.1 %	10	$308 -42%
HC Wainwright & Co.	57 %	+24.6 %	14	$660 +25%
Morgan Stanley	57 %	+12.1 %	7	$519 -2%
Oppenheimer	57 %	+10.5 %	7	$600 +14%
Argus Research	60 %	+1.5 %	5	$400 -24%

In short — Should you invest in United Therapeutics? Is it too late, still worth it? Analysts are fairly positive (78% buy, median target $660, i.e. +25%), and the most reliable on UTHR targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

78% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
Median price target $660, i.e. +25% from the current price ($528).
The most reliable firm on UTHR, Jefferies (75% hit rate, 4 scored calls), targets $564 (call made on September 2, 2025, maturing on September 2, 2026) (+7%) in its most recent call.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 9 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on UTHR

Median target $660 (+25%) · 9 ratings · Buy consensus

Strong Buy00%

Buy778%

Hold222%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in United Therapeutics now?

We won't decide for you. The facts: 78% of analysts rate it a buy, median target $660 (+25%), and Jefferies (most reliable on UTHR, 75%) targets $564. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in United Therapeutics?

Not according to analysts: the median target ($660) is still +25% above the current price ($528) (most reliable on UTHR: Jefferies, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is United Therapeutics still worth investing in?

It depends on the gap between the price ($528) and its estimated value: analysts target $660 on median (+25%), with 78% buys (most reliable on UTHR: Jefferies, 75%). Cross-check with their real reliability on UTHR and the cautions above. Information, not advice.

What's the main risk in buying UTHR?

The consensus is not unanimous: of 9 ratings, 2 are neutral.

→ Go deeper: the full United Therapeutics profile (consensus, analyst reliability, price target, performance).